Author Archives: Guest Blogger

Value-Based Assessment in the UK: The Patient View

By Leela Barham. Patients are influential in the UK when it comes to access to medicines: their individual stories are highlighted in the media and the groups that represent them are credited with major policies. For example, the Rarer Cancer Foundation (RCF) has been credited in large part with the introduction of the Cancer Drugs […]
Posted in Europe, Guest Blog, Op-Ed, pricing | Tagged , , , , , , | Leave a comment

European Pharma Policy Reaches "New Level of Timidity"

By Peter O’ Donnell, Applied Clinical Trials. The European Union has managed to snatch defeat from the jaws of opportunity once more! A long-heralded document portentously entitled “Pharmaceutical industry: a strategic sector for the European economy,” and supposedly initiating a new start in long-term thinking about boosting the drug industry, squeezes the thinnest and weakest […]
Posted in Europe, Guest Blog, Op-Ed, Regulatory | Tagged , , | Leave a comment

Industry Challenged: “Do More for Teenagers with Cancer”

By Leela Barham. Accessing the latest cancer drugs always seem to be controversial. Not just because of the money but also because of the complexities of accessing treatments during their development. This seems to be especially the case for young people with cancer, according to the UK’s Teenage Cancer Trust.¬†
Posted in Europe, Global, Guest Blog, R&D | Tagged , , , | Leave a comment

Value-Based Assessment in the UK: The Industry View

By Leela Barham. In the UK, Value-Based Pricing (VBP) has morphed into Value-Based Assessment (VBA), with the National Institute for Health and Care Excellence (NICE) tasked with taking the loose policy concepts (established as far back as 2010) and actually implementing them. Earlier this year, NICE set out its approach, which boiled down to¬†taking a […]
Posted in Europe, Global, Guest Blog, pricing, Regulatory | Tagged , , , , , , | Leave a comment

Show Me the Money: First New PPRS Payments in UK

By Leela Barham. The Pharmaceutical Price Regulation Scheme (PPRS) is a long-standing scheme where the pharmaceutical industry, represented by the Association of the British Pharmaceutical Industry (ABPI), negotiates with the Department of Health (DH) to agree how to indirectly manage the price of branded medicines. Its latest incarnation includes a brand new feature. Instead of […]
Posted in Europe, Global, Guest Blog, Op-Ed, pricing | Tagged , , , , | Leave a comment
  • Categories

  • Meta